Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Investors Business Daily

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Fortune

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Lisa Jarvis: Eli Lilly’s new weight-loss drug is even better than Ozempic

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

Tribune News Service

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400%

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.

Investors Business Daily

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

Why Lilly's Obesity Treatment Update Sent Novo, Madrigal And Viking Shares Diving

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Fortune

Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout

Dice stock skyrocketed Tuesday after Eli Lilly pledged to buy the immunology-focused biotech company for $2.4 billion.

Investors Business Daily

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million

Eli Lilly inked a gene-editing collaboration with Verve Therapeutics that gave the young biotech "pharma validation."

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Investors Business Daily

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review

The major indexes retreated for most of the week on banking fears, but rebounded Friday on a strong jobs report and bank stocks roaring back.

WEKU

Eli Lilly says an experimental drug slows Alzheimer's worsening

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced.

Get all your
news in one place.

100’s of premium titles.
One news app.

Al Jazeera

‘Remarkable’ drug reduces Alzheimer’s decline, study shows

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

The Guardian - UK

New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

AFP

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

Washington (AFP) - US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

The Independent UK

Eli Lilly says experimental drug slows Alzheimer's worsening

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

AFP

'Remarkable' Alzheimer drug reduces cognitive decline, results show

Washington (AFP) - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts.

Investors Business Daily

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

Investors Business Daily

Lilly Has Plans For Possible Anti-Obesity Medication. Here's How To Make Money With LLY Options

This trade is a neutral to bullish position and anticipates the stock holding above 390 over the summer term.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.